Marissa Pierce
Family · San Antonio, TXNPI 1841749595
Payments from drug & device makers
Across 73 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$230
- Lilly USA, LLC$184
- GSK$155
- Merck$119
- Pfizer$104
- Novo Nordisk$94
- plus $440 from 14 others
What the payments were for
- Food & beverage$1,326100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $230 |
| Lilly USA, LLC | 9 | $184 |
| GSK | 8 | $155 |
| Merck | 6 | $119 |
| Pfizer | 6 | $104 |
| Novo Nordisk | 6 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $70 |
| Exact Sciences | 3 | $65 |
| AbbVie | 3 | $55 |
| Abbott | 2 | $46 |
| Medtronic | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Bayer | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Althera Pharmaceuticals LLC | 1 | $14 |
How this compares
$1,326 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $46,030 |
| FarxigaDapagliflozin Propanediol | 26 | $34,377 |
| EliquisApixaban | 18 | $24,782 |
| Bydureon BciseExenatide Microspheres | 12 | $20,466 |
| JanuviaSitagliptin Phosphate | 12 | $17,460 |
| RybelsusSemaglutide | 11 | $14,010 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,887 |
| Atorvastatin Calcium | 105 | $1,235 |
| Omeprazole | 70 | $1,025 |
| Gabapentin | 49 | $922 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $910 |
| ValacyclovirValacyclovir Hcl | 19 | $888 |
| Duloxetine Hcl | 31 | $773 |
| Pravastatin Sodium | 47 | $771 |
| Levothyroxine Sodium | 81 | $762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $94 | $60,04048 claims |
| AstraZenecaFarxiga | $230 | $34,37726 claims |
| PfizerEliquis | $104 | $24,78218 claims |
| MerckJanuvia | $119 | $17,46012 claims |
| AbbVieSynthroid | $55 | $67316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.